By means of its ability to act as co-receptor, binding to and presenting growth factors to their cognate RTK, CSPG4 could potentiate the activation of the mitogen-activated protein kinases (MAPK) pathway, resulting in the selective growth and survival advantage of CSPG4-positive tumor cells [50, 51]. The gene discussed is CSPG4; the disease is neoplasm.